Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study.

American journal of hematology - 1 May 2015

Doubek Michael, Brychtova Yvona, Panovska Anna, Sebejova Ludmila, Stehlikova Olga, Chovancova Jana, Malcikova Jitka, Smardova Jana, Plevova Karla, Volfova Pavlina, Trbusek Martin, Mraz Marek, Bakesova Denisa, Trizuljak Jakub, Hadrabova Marketa, Obrtlikova Petra, Karban Josef, Smolej Lukas, Oltova Alexandra, Jelinkova Eva, Pospisilova Sarka, Mayer Jiri

Abstract excerpt

The treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) remains a challenging clinical issue. An important treatment option is the use of high-dose corticosteroids. The purpose of this clinical trial was to determine the efficacy and toxicity of an ofatumumab-dexamethasone (O-Dex)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dexamethasone

Share to Drug Administration Schedule

Share to Drug Therapy, Combination

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Recurrence

Share to Survival Analysis

Source

Identifiers

PMID: 25645263
DOI: 10.1002/ajh.23964

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25645263-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study.PMID 25645263Read ↗

The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia.Semantic proximity Read ↗

Update on therapy of chronic lymphocytic leukemia.Semantic proximity Read ↗

Optimizing frontline therapy of CLL based on clinical and biological factors.Semantic proximity Read ↗

Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE studySemantic proximity Read ↗

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial resultsSemantic proximity Read ↗

Ofatumumab as Part of Reduced Intensity Conditioning in High Risk B-cell Lymphoma Patients: Final Long-term Analysis From a Prospective Multicenter Phase-ii TrialSemantic proximity Read ↗

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.Semantic proximity Read ↗

Dexamethasone in hyperleukocytic acute myeloid leukemia.Semantic proximity Read ↗

Evaluating Axatilimab as a treatment option for chronic graft-versus-host diseaseSemantic proximity Read ↗

Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trialSemantic proximity Read ↗

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.Semantic proximity Read ↗

Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.